UNIQURE
uniQure is a leader in the field of gene therapy and had developed the first and currently the only gene therapy product to receive regulatory approval in the European Union. Gene therapy offers the prospect of long-term and potentially curative benefit to patients with genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration. Our first product, Glybera, was approved by the European Commi... ssion in October 2012 under exceptional circumstances for the treatment of a subset of patients with lipoprotein lipase deficiency, or LPLD, a potentially life-threatening, orphan metabolic disease. We are also developing a pipeline of additional adeno-associated virus (AAV)-based gene therapies through multiple collaborations. We develop our gene therapies using our innovative, modular technology platform, including our proprietary manufacturing process. We initially are focused on orphan diseases but believe that we will also be able to develop gene therapies targeting chronic and degenerative diseases that affect larger populations.
UNIQURE
Industry:
Biotechnology Genetics Health Care Medical
Founded:
1998-01-01
Address:
Amsterdam, Noord-Holland, The Netherlands
Country:
The Netherlands
Website Url:
http://www.uniqure.com
Total Employee:
501+
Status:
Active
Contact:
+31 20 566 7394
Total Funding:
780.74 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving SPF Apple Mobile Web Clips Icon Google Analytics Google Maps Content Delivery Network SSL By Default Google Universal Analytics
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
AMSilk
AMSilk produces and distributes high-quality silk biopolymers.
CasZyme
CasZyme is a biotech firm that is involved in research & development of cas proteins and CRISPR based molecular tools.
CimCure
CimCure focuses on design and development of a novel class of active cancer immunotherapies.
LYSOGENE
Lysogene is a pioneer in the basic research and clinical development of gene therapy for neurodegenerative disorders.
Medicinal Genomics
Medicinal Genomics is pioneering the genomics of medical cannabis and hemp.
Nuclidium
Nuclidium’s vision is to address the unmet need to detect and stage cancer more accurately.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Versameb
Versameb is focusing on the discovery and development of innovative, next-generation RNA-based drugs.
Whitehead Institute for Biomedical Research
Whitehead Institute is a research institution for human health.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-06-23 | Corlieve Therapeutics | Corlieve Therapeutics acquired by UniQure | 46.3 M EUR |
| 2014-08-12 | InoCard | InoCard acquired by UniQure | N/A |
Investors List
Hercules Capital
Hercules Capital investment in Post-IPO Debt - UniQure
Forbion Capital Partners
Forbion Capital Partners investment in Private Equity Round - UniQure
Chiesi Farmaceutici
Chiesi Farmaceutici investment in Private Equity Round - UniQure
Coller Capital
Coller Capital investment in Private Equity Round - UniQure
Official Site Inspections
http://www.uniqure.com Semrush global rank: 7.01 M Semrush visits lastest month: 936
- Host name: 104.17.124.41
- IP address: 104.17.124.41
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "UniQure"
UniQure - Crunchbase Company Profile & Funding
UniQure is a leader in the field of gene therapy and had developed the first and currently the only gene therapy product to receive regulatory approval in the …See details»
uniQure - The Org
UniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. They are leveraging their modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic …See details»
uniQure Company Profile | Management and Employees List
Find contact information for uniQure. Learn about their Pharmaceuticals, Manufacturing market share, competitors, and uniQure's email format. Company Overview ... Founded in 1998 and headquartered in Amsterdam, Netherlands, uniQure is an organization that targets single …See details»
Our Leadership | Pioneers & Leaders - uniQure
For most of his career, Dr. Gut worked at Novo Nordisk Inc. (NYSE: NVO), where he headed the company’s U.S. Biopharm Medical organization with leading products in hemophilia, endocrinology, and women’s health (NovoSeven ®, Norditropin ®, and Vagifem ®), totaling …See details»
UniQure Org Chart + Executive Team - The Official Board
Organizational Chart of UniQure. UniQure Org Chart www.uniqure.com. has 15 executives +31 205 667 394; Add an executive. UniQure (QURE) News . Anything missing? We search for you. Print or download . CEO & Director. Matthew Kapusta. Move. Chairman of the Board. David …See details»
UniQure - Funding, Financials, Valuation & Investors - Crunchbase
UniQure is registered under the ticker NASDAQ:QURE . Their stock opened with $29.50 in its Feb 6, 2014 IPO. UniQure is funded by 4 investors. Hercules Capital and Forbion Capital Partners are the most recent investors. UniQure has acquired 2 organizations. Their most recent acquisition …See details»
uniQure - LinkedIn
UniQure | 22,684 followers on LinkedIn. Transforming the lives of patients through gene therapy | uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a …See details»
uniQure Company Profile - Office Locations, Competitors, Revenue ...
Oct 29, 2024 uniQure has 5 employees across 5 locations and $27.12 m in annual revenue in FY 2024. See insights on uniQure including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
UniQure Shares Soar After Latest FDA Designation for …
By Denny Jacob. Gene therapy developer uniQure shares soared 46% in premarket trading after its treatment for Huntington's disease received breakthrough therapy designation from the Food and Drug ...See details»
uniQure | A Global Leader in Gene Therapy
UniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease; May 7, 2024 uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress; Feb 28, 2024 …See details»
Corporate Governance | Investors & Media - uniQure
UniQure Stock Ownership Guidelines PDF; More on Investors & Media. Press Releases Events & Presentations Shareholder Info uniQure. uniQure N.V. Paasheuvelweg 25a, 1105 BP Amsterdam Chamber of Commerce 34275365. Pioneers & Leaders; Patients & Families ...See details»
uniQure Announces FDA Breakthrough Therapy Designation
7 hours ago uniQure Forward-Looking Statements . This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the ...See details»
Social Responsibility | Culture & Careers - uniQure
In 2022, we established an environmental, social and governance (ESG) committee to provide oversight and to ensure that we develop the right programs and policies across our organization. This Committee, which is chaired by …See details»
Working at uniQure | Culture & Careers
Working together across the organization, we can achieve far more, faster, than even the most talented individual. When we collaborate together, we grow together. Innovate every day. Breakthrough innovation comes from imagination. We seek the new, the unconventional, the …See details»
uniQure - Overview, News & Similar companies | ZoomInfo.com
Aug 6, 2024 Founded in 1998 and headquartered in Amsterdam, Netherlands, uniQure is an organization that targets single treatments using gene therapy. uniQure's Social Media. Is this data correct? View contact profiles from uniQure. Popular Searches Uniqure Nv UniQure …See details»
uniQure, Inc. - MassBio
UniQure is a leading gene therapy company advancing transformative therapies for patients with severe medical needs. It is working to deliver on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology …See details»
Mission, Vision & Core Values of UniQure – CANVAS, SWOT, …
Dec 19, 2024 These guiding principles provide a clear direction for the organization, helping to align all stakeholders towards a common goal and purpose. Mission: UniQure's mission statement focuses on the research and early development of human gene-based therapies. This mission …See details»
uniQure Announces Strategic Reorganization to Reduce
Oct 5, 2023 FOR INVESTORS: FOR MEDIA: Maria E. Cantor: Chiara Russo: Tom Malone Direct: 339-970-7536 Mobile: 617-680-9452 [email protected]: Direct: 617-306-9137See details»
Our Story | Pioneers & Leaders - uniQure
UniQure is delivering on the promise of gene therapy – a single treatment with curative results – through an innovative adeno-associated virus (AAV)-based technology platform supported by proprietary commercial-grade manufacturing. The recent approvals of our gene therapy for …See details»
uniQure Announces Strategic Reorganization to Reduce Operating …
Oct 5, 2023 uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs uniQure Inc. Thu, Oct 5, 2023, 4:05 AM 6 min readSee details»